Skip to content
logo
  • Home
  • About
    • About GSAM
    • Our Team
    • PEACE
  • Resources
    • About Addiction
    • GSAM NEWS
    • Links
    • Conference
  • GSAM NEWS
  • Contacts
  • Members
    • GSAM 2025-2027 Call for Vote
    • Become A Member
    • Login
    • My GSAM Account
    • Members Roster
    • Member Events
    • Chapter Meetings Minutes & Agendas
    • Member’s Only Discussions
    • Chapter Documents
      • ASAM Chapter Affiliation Agreement
      • ASAM Chapter Agreement
      • Constitution and Bylaws
    • Member Resources
      • Practice Management Resources
      • Report Pharmacy Access Issues

Annual Conference

Nominations

No products in the cart.

logo
  • Home
  • About
    • About GSAM
    • Our Team
    • PEACE
  • Resources
    • About Addiction
    • GSAM NEWS
    • Links
    • Conference
  • GSAM NEWS
  • Contacts
  • Members
    • GSAM 2025-2027 Call for Vote
    • Become A Member
    • Login
    • My GSAM Account
    • Members Roster
    • Member Events
    • Chapter Meetings Minutes & Agendas
    • Member’s Only Discussions
    • Chapter Documents
      • ASAM Chapter Affiliation Agreement
      • ASAM Chapter Agreement
      • Constitution and Bylaws
    • Member Resources
      • Practice Management Resources
      • Report Pharmacy Access Issues

Annual Conference

Nominations

No products in the cart.

  • Home
  • About
    • About GSAM
    • Our Team
    • PEACE
  • Resources
    • About Addiction
    • GSAM NEWS
    • Links
    • Conference
  • GSAM NEWS
  • Contacts
  • Members
    • GSAM 2025-2027 Call for Vote
    • Become A Member
    • Login
    • My GSAM Account
    • Members Roster
    • Member Events
    • Chapter Meetings Minutes & Agendas
    • Member’s Only Discussions
    • Chapter Documents
      • ASAM Chapter Affiliation Agreement
      • ASAM Chapter Agreement
      • Constitution and Bylaws
    • Member Resources
      • Practice Management Resources
      • Report Pharmacy Access Issues
Methadone-Buprenorphine Transfers Using Low Dosing of Buprenorphine: An Open-Label, Nonrandomized Clinical Trial
Articles of Interest
0
0
December 11, 2024

Methadone-Buprenorphine Transfers Using Low Dosing of Buprenorphine: An Open-Label, Nonrandomized Clinical Trial

Abstract

Aims

To compare a low-dosing protocol to standard practice for methadone-buprenorphine transfers.

Methods

We undertook a nonrandomized open-label clinical trial across 8 sites from NSW, Australia. Participants prescribed methadone wishing to transfer to buprenorphine could either choose or be randomized to a low-dose transfer or standard care transfer as per NSW health guidelines. The low-dose protocol started at 0.2 mg BD and increased to 16 mg on day 6, with flexible dosing thereafter. The primary outcome was continuation of buprenorphine 1 week post-transfer. Binary logistic regression was used to access the primary outcome with demographic differences between the groups included as covariates.

Results

There were 117 participants who commenced the study, 101 in the low-dose arm and 16 in standard care. Mean methadone dose was 82 mg in the low-dose arm and 46 mg in standard care. The primary outcome was met by 81 participants in the low-dose arm (80%) and 13 participants in standard care (81%). There was no significant between-arm difference in the odds of the primary outcome (OR = 2.22; 95% CI: 0.45–10.91; P = 0.327). Four participants (4%) in the low-dose arm experienced precipitated withdrawal against 1 (6%) in standard care. Higher methadone dose decreased the odds of successful transfer by 20% (OR = 0.8 per 10 mg methadone; 95% CI: 0.7–0.99; P = 0.04). Withdrawal scores between the 2 arms were similar.

Conclusions

We were unable to detect a difference between low dosing and standard care for methadone to buprenorphine transfers. Increasing methadone dose was a predictor of success; setting (ambulatory or inpatient) was not.

View the Full Article at the Journal of Addiction Medicine
Georgia Society of Addiction Medicine
Author: Georgia Society of Addiction Medicine

ASAM/GSAM Chapter Engagement Manager

Share

Post navigation

Prev
Next

Leave a Comment Cancel reply

Your email address will not be published. Required fields are marked *

The Georgia Society of Addiction Medicine 

Social Media

Recent Posts

  • Georgians for Responsible Marijuana Policy: Important Marijuana Study Committee Hearing Tomorrow October 24, 2025
  • The Joint Clinical Practice Guideline on Benzodiazepine (BZD) Tapering October 15, 2025

Quick News

Another Brilliant Design by: Adwebvertising…It’s Like Advertising…Only Better!

Copyright © 2022, Georgia Society of Addiction Medicine. All Rights Reserved